Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing ...

As previously reported, William Blair downgraded NeoGenomics (NEO) to Market Perform from Outperform after the company reported Q2 results and cut ...

Exelixis Q2 revenue missed estimates, but strong Cabometyx sales lifted earnings. STELLAR trial delays and strategy shifts ...

Cardiff Oncology has reported updated results from its phase 2 colorectal cancer trial, laying out data that it believes can ...

Sarepta Therapeutics shares snapped a three-day losing streak on Tuesday, as analysts said resumption of U.S. shipments for ...

Incyte posts strong Q2 results driven by Jakafi and Opzelura growth, lifts 2025 guidance despite challenges in future product development.

William Blair downgraded NeoGenomics (NEO) to Market Perform from Outperform. Published first on TheFly – the ultimate source for real-time, ...

Acquisition to expand, enhance and strengthen network capabilities across the insurance claims and restoration ecosystem ...

Executives at the laboratory companies said they expect the effects on testing services from the Republicans’ tax and ...

SoFi Technologies shines in Q2 2025 with record revenue, robust member growth, blockchain & crypto innovation, and raised guidance.

Global Industrial Company posts record Q2 2025 performance with 3.2% revenue growth, margin gains, and strategic shifts toward customer-centricity ...

Manhattan Associates delivered a positive Q2, with the market responding strongly to the company's better-than-expected results. Management attributed the quarter’s outperformance to robust growth in ...